BIOMAT Database Logo BIOMAT Database Logo

Comparison of immune parameters in patients with one or two primary malignant neoplasms. 1993

C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
Department of Immunology, Hellenic Anticancer Institute, Athens, Greece.

The purpose of this study was to correlate cellular immune responses and cytokine production in vitro between patients with one or two primary malignant neoplasms. One hundred and ninety-three patients (110 patients with one primary malignant neoplasm (group I), and 83 patients with two primary tumors (group II), entered this study. Mononuclear cells isolated from peripheral blood were tested in the following tests: (a) proliferative responses in the autologous and allogeneic mixed lymphocyte reaction (auto- and allo-MLR respectively): (b) natural killer cell activity; (c) production of interleukin-2 during the allo-MLR, and (d) interleukin-1 beta production by lipopolysaccharide-stimulated monocytes. All these parameters were found to be decreased in cancer patients as compared to normal donors (p < 10(-3)). In addition, we were able to detect significant differences between the values obtained from patients in groups I and II (p < 10(-2)). These data suggest a further impairment in cancer patients' immune status after the diagnosis of a second malignancy.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females

Related Publications

C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
TWO PRIMARY MALIGNANT NEOPLASMS IN ONE PATIENT.
September 1961, The British journal of ophthalmology,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
[Primary multiple malignant neoplasms of one breast].
April 1976, Khirurgiia,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
[Circulating immune complexes in patients with malignant neoplasms].
January 1986, Voprosy onkologii,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
Four primary, malignant, random neoplasms in one patient.
April 1979, Southern medical journal,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
[Registration of patients with multiple primary malignant neoplasms].
January 2000, Voprosy onkologii,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
[Definition of immune status in patients with malignant gynecologic neoplasms].
July 1979, Archives of gynecology,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
[Second primary malignant neoplasms in patients with laryngeal neoplasms. Cytologic screening tests].
January 1995, Otolaryngologia polska = The Polish otolaryngology,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
[Acute pneumonia in patients with multiple primary malignant neoplasms].
January 1993, Terapevticheskii arkhiv,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
[Primary multiple malignant neoplasms in patients with skin melanoma].
January 2008, Likars'ka sprava,
C N Baxevanis, and G J Reclos, and A D Gritzapis, and G V Dedousis, and P Arsenis, and A Katsiyiannis, and P G Mitsis, and N Tsavaris, and M Papamichail
Multiple primary malignant neoplasms in patients with esophageal cancer.
January 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus,
Copied contents to your clipboard!